Cost-effectiveness of percutaneous tibial nerve stimulation versus extended release tolterodine for overactive bladder

Journal of Urology

Volumn 187, Issue 1, 2012, Pages 178-184

  Chen, Heidi W ^a   Bercik, Richard S ^a   Werner, Erika F ^a   Thung, Stephen F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cost benefit analysis; overactive; tibial nerve; tolterodine; urge; urinary bladder; urinary incontinence

Indexed keywords

TOLTERODINE;

ARTICLE; CONTINENCE; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; NERVE STIMULATION; OVERACTIVE BLADDER; PERCUTANEOUS TIBIAL NERVE STIMULATION; PRIORITY JOURNAL; QUALITY OF LIFE; TIBIAL NERVE; TREATMENT DURATION; TREATMENT OUTCOME; URINE INCONTINENCE;

BENZHYDRYL COMPOUNDS; COST-BENEFIT ANALYSIS; CRESOLS; DECISION TREES; DELAYED-ACTION PREPARATIONS; FEMALE; HUMANS; MUSCARINIC ANTAGONISTS; PHENYLPROPANOLAMINE; TIBIAL NERVE; TRANSCUTANEOUS ELECTRIC NERVE STIMULATION; URINARY BLADDER, OVERACTIVE;

EID: 83555164635     PISSN: 00225347     EISSN: 15273792     Source Type: Journal    
DOI: 10.1016/j.juro.2011.09.052     Document Type: Article

References (30)

1. T.W. Hu, T.H. Wagner, and J.D. Bentkover Estimated economic costs of overactive bladder in the United States Urology 61 2003 1123
2. A.O. D'Souza, M.J. Smith, and L.A. Miller Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan J Manag Care Pharm 14 2008 291
3. M.R. van Balken, V. Vandoninck, and K.W. Gisolf Posterior tibial nerve stimulation as neuromodulative treatment of lower urinary tract dysfunction J Urol 166 2001 914
4. K.M. Peters, S.A. Macdiarmid, and L.S. Wooldridge Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the Overactive Bladder Innovative Therapy trial J Urol 182 2009 1055
5. S.A. MacDiarmid, K.M. Peters, and S.A. Shobeiri Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder J Urol 183 2010 234
6. F.E. Govier, S. Litwiller, and V. Nitti Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study J Urol 165 2001 1193
7. P. Siami, L.S. Seidman, and D. Lama A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: the speed of onset of therapeutic assessment trial (STAT) Clin Ther 24 2002 616
8. M. Takei, Y. Homma Japanese Tolterodine Study Group Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder in Japanese patients Int J Urol 12 2005 456
9. R.B. Congregado, O. Pena, and M.P. Campoy Peripheral afferent nerve stimulation for treatment of lower urinary tract irritative symptoms Eur Urol 45 2004 65
10. G. Nabi, J.D. Cody, and G. Ellis Anticholinergic drugs versus placebo for overactive bladder syndrome in adults Cochrane Database Syst Rev 4 2006 CD003781
11. K. Kreder, C. Mayne, and U. Jonas Long-term safety, tolerability and efficacy of extended-release tolterodine in the treatment of overactive bladder Eur Urol 41 2002 588
12. M. Gopal, K. Haynes, and S.L. Bellamy Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms Obstet Gynecol 112 2008 1311
13. M.R. van Balken, H. Vergunst, and B.L. Bemelmans Prognostic factors for successful percutaneous tibial nerve stimulation Eur Urol 49 2006 360
14. V. Vandoninck, M.R. Van Balken, and E. Finazzi-Agro Posterior tibial nerve stimulation in the treatment of urge incontinence Neurourol Urodyn 22 2003 17
15. F. van der Pal, M.R. van Balken, and J.P. Heesakkers Percutaneous tibial nerve stimulation in the treatment of refractory overactive bladder syndrome: is maintenance treatment necessary? BJU Int 97 2006 547
16. Medicare Physician Fee Schedule, Centers for Medicare and Medicaid Services http://www.cms.gov/apps/physician-fee-schedule/ Accessed August 17, 2011
17. National wholesale price Yale New Haven Hospital pharmacy, personal communication August 2010
18. L.L. Subak, L. Brubaker, and T.C. Chai High costs of urinary incontinence among women electing surgery to treat stress incontinence Obstet Gynecol 111 2008 899
19. J.M. Wu, R.G. Fulton, and C. Amundsen Quality of life for different overactive bladder severities and treatments Female Pelvic Med Reconstr Surg 16 2010 S151
20. E. Finazzi Agro, A. Campagna, and F. Sciobica Posterior tibial nerve stimulation: is the once-a-week protocol the best option? Minerva Urol Nefrol 57 2005 119
21. S. Herschorn, S. Swift, and Z. Guan Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial BJU Int 105 2010 58
22. H.C. Klingler, A. Pycha, and J. Schmidbauer Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study Urology 56 2000 766
23. R. Freeman, S. Hill, and R. Millard Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine Obstet Gynecol 102 2003 605
24. E.M. Perfetto, P. Subedi, and Z. Jumadilova Treatment of overactive bladder: a model comparing extended-release formulations of tolterodine and oxybutynin Am J Manag Care 11 2005 S150
25. J.M. Wu, N.Y. Siddiqui, and C.L. Amundsen Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence J Urol 181 2009 2181
26. E. Finazzi-Agro, F. Petta, and F. Sciobica Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial J Urol 184 2010 2001
27. J.T. King Jr, J. Tsevat, and J.R. Lave Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation Med Decis Making 25 2005 667
28. K.M. Peters, D.J. Carrico, and R.A. Perez-Marrero Randomized trial of percutaneous tibial nerve stimulation versus sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial J Urol 183 2010 1438
29. M. Johannesson, R.M. O'Conor, and G. Kobelt-Nguyen Willingness to pay for reduced incontinence symptoms Br J Urol 80 1997 557
30. L.L. Subak, J.S. Brown, and S.R. Kraus The "costs" of urinary incontinence for women Obstet Gynecol 107 2006 908